Way to make one-way flu vaccine discovered

A new process to make a one-time, universal influenza vaccine has been discovered by a researcher at Georgia State University's Center for Inflammation, Immunity and Infection and his partners.

Associate Professor Sang-Moo Kang and his collaborators have found a way to make the one-time vaccine by using recombinant genetic engineering technology that does not use a seasonal virus.

Instead, the new vaccine uses a virus' small fragment that does not vary among the different strains of .

By using the fragment and generating particles mimicking a virus in structure, the immune system can learn to recognize any type of flu virus and attack the pathogen, preventing illness. The research appears in a recent edition of the journal Molecular Therapy, published by the .

"We can now design a vaccine that makes it easier to induce a good to recognize a pathogen, regardless of how the surface proteins of the virus change," Kang said.

Health officials and scientists must alter flu vaccines every year to match expected strains, and often shortages can result, such as what happened during the 2009 Swine . A one-time vaccine would prevent such a scenario, Kang said.

"Outbreaks of pandemic can be a dangerous situation, and our current vaccination procedures are not perfect," he said.

Using the new one-time vaccine, using only a fragment rather than the live viral vaccine, such as FluMist, or a killed virus itself, would be safer for people with weakened immune systems, young children and the elderly, Kang said.

The team included researchers from Georgia State, the Emory Vaccine Center at the Emory University School of Medicine, Sungshin Women's University in South Korea and the Animal, Plant and Fisheries Quarantine and Inspection Agency in South Korea.

More information: The article is "Virus-like particles containing multiple M2 extracellular domains confer improved cross protection against various subtypes of influenza virus," Nature Molecular Therapy, dx.doi.org/10.1038/MT.2012.246

Related Stories

FDA approves first 4-in-1 flu vaccine

Feb 29, 2012

Federal health officials have approved the first vaccine that protects against four strains of the common flu, offering one additional layer of protection against the influenza virus that affects millions each year.

NIH experts describe influenza vaccines of the future

Nov 17, 2010

In a review article appearing in the New England Journal of Medicine, scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, examine research under way to ...

Recommended for you

No added benefit proven for umeclidinium/vilanterol in COPD

4 hours ago

The drug combination umeclidinium/vilanterol (trade name Anoro) has been approved since May 2014 for adults with chronic obstructive pulmonary disease (COPD). In an early benefit assessment pursuant to the Act on the Reform ...

Ebola vaccine not before late 2016: GSK researcher

Oct 17, 2014

An Ebola vaccine by British pharmaceuticals giant GlaxoSmithKline may not be ready for commercial use until late 2016 and should therefore not be seen as the "primary answer" to the current outbreak, a company researcher ...

Chimerix gets FDA OK to test drug for Ebola

Oct 17, 2014

(AP)—A North Carolina drugmaker plans to test its experimental antiviral drug in patients who have Ebola, after getting authorization from regulators at the Food and Drug Administration.

Esbriet, ofev approved to treat deadly lung disease

Oct 16, 2014

(HealthDay)—Two new drugs have been approved by the U.S. Food and Drug Administration to treat progressive lung scarring from an uncertain cause, medically called idiopathic pulmonary fibrosis (IPF).

FDA weighs removing bolded warning from Chantix

Oct 14, 2014

(AP)—The Food and Drug Administration will ask a panel of experts later this week whether a bold-letter warning on the anti-smoking drug Chantix should be removed based on company-supported evidence that the drug does not ...

User comments